FDA Approvals, News & UpdatesMultiple MyelomaNewsworthy

Darzalex-Based Regimen Approved as First Treatment in Patients with Multiple Myeloma Ineligible for Transplant

August 2019 Vol 5 No 4

In June 2019, the FDA approved Darzalex (daratumumab; from Janssen) in combination with Revlimid (lenalidomide; from Celgene) and dexamethasone as the first treatment in patients with multiple myeloma who cannot undergo a stem-cell ­transplant. Darzalex was previously approved for different uses in patients with multiple myeloma.

This latest approval was based on a clinical trial of patients with newly diagnosed multiple myeloma who were not candidates for chemotherapy and a transplant.

Adding Darzalex to the Revlimid plus dexamethasone regimen prolonged the time without disease progression compared with Revlimid plus dexamethasone alone. At the time of the analysis, the average time to disease progression was not reached in patients who received Darzalex (meaning their cancer continues to respond to therapy), but in patients who did not receive Darzalex, the average time to disease progression was 31.9 months.

Adding Darzalex also led to more patients achieving complete response (no sign of cancer) than patients who received only Revlimid and dexamethasone.

Recommended For You
Multiple Myeloma
Drugs for Multiple Myeloma
Here are the drugs and financial support services available to patients receiving treatment for Multiple Myeloma.
LeukemiaLymphomaMultiple Myeloma
Working with Your Treatment Team to Decide on the Best Options for You
People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team.
Multiple Myeloma
New Study Shows Racial Disparities Still Common in the Treatment of Patients with Multiple Myeloma
By Dana Taylor
Among Americans diagnosed with multiple myeloma, black and Hispanic patients receive their first treatment about 3 months later than white patients. Delays in treatment means unnecessary complications. Closing this racial gap is therefore paramount.
Last modified: August 28, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.